{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:25:59Z","timestamp":1782782759891,"version":"3.54.5"},"reference-count":19,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,3]],"date-time":"2025-07-03T00:00:00Z","timestamp":1751500800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.cgh.2025.06.020","type":"journal-article","created":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T12:59:23Z","timestamp":1751633963000},"page":"210-220.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity"],"prefix":"10.1016","volume":"24","author":[{"given":"Andres J.","family":"Yarur","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Reinisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina B.","family":"Gecse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesse","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arcangelo M.","family":"Abbatemarco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Goetsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krisztina","family":"Lazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gokul","family":"Pradeep","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce E.","family":"Sands","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2025.06.020_bib1","doi-asserted-by":"crossref","first-page":"384","DOI":"10.14309\/ajg.0000000000000152","article-title":"ACG clinical guideline: ulcerative colitis in adults","volume":"114","author":"Rubin","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.020_bib2","first-page":"59","article-title":"A practical clinical approach to the management of high-risk ulcerative colitis","volume":"17","author":"Rubin","year":"2021","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cgh.2025.06.020_bib4","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1038\/ajg.2015.233","article-title":"Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target","volume":"110","author":"Peyrin-Biroulet","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.020_bib5","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1053\/j.gastro.2020.12.031","article-title":"STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the International Organization for the Study of IBD (IOIBD): determining therapeutic goals for treat-to-target strategies in IBD","volume":"160","author":"Turner","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.06.020_bib6","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1056\/NEJM198712243172603","article-title":"Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study","volume":"317","author":"Schroeder","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.06.020_bib7","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cgh.2010.12.028","article-title":"Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis","volume":"9","author":"Ardizzone","year":"2011","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.020_bib8","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1053\/j.gastro.2011.06.054","article-title":"Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis","volume":"141","author":"Colombel","year":"2011","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.06.020_bib9","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1136\/gut.2003.038505","article-title":"Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk","volume":"53","author":"Rutter","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2025.06.020_bib10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1093\/gastro\/gox016","article-title":"Ulcerative Colitis Endoscopic Index of Severity (UCEIS) versus Mayo Endoscopic Score (MES) in guiding the need for colectomy in patients with acute severe colitis","volume":"6","author":"Xie","year":"2018","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.cgh.2025.06.020_bib11","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0140-6736(23)00061-2","article-title":"Etrasimod as induction and maintenance therapy for ulcerative colitis (ELEVATE): two randomised, double-blind, placebo-controlled, phase 3 studies","volume":"401","author":"Sandborn","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2025.06.020_bib12","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cgh.2016.08.044","article-title":"Efficacy of vedolizumab induction and maintenance therapy in patients with ulcerative colitis, regardless of prior exposure to tumor necrosis factor antagonists","volume":"15","author":"Feagan","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.020_bib13","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1053\/j.gastro.2011.10.032","article-title":"Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis","volume":"142","author":"Sandborn","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2025.06.020_bib14","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1056\/NEJMoa2033617","article-title":"Ozanimod as induction and maintenance therapy for ulcerative colitis","volume":"385","author":"Sandborn","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.06.020_bib15","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.cgh.2021.02.043","article-title":"Efficacy and safety of tofacitinib in ulcerative colitis based on prior tumor necrosis factor inhibitor failure status","volume":"20","author":"Sandborn","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2025.06.020_bib16","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa1900750","article-title":"Ustekinumab as induction and maintenance therapy for ulcerative colitis","volume":"381","author":"Sands","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cgh.2025.06.020_bib17","doi-asserted-by":"crossref","first-page":"i8","DOI":"10.1093\/ecco-jcc\/jjac190.0004","article-title":"OP04 efficacy of upadacitinib in ulcerative colitis: a phase 3 post hoc analysis of biologic- and anti-TNF-inadequate response patients","volume":"17","author":"Vermeire","year":"2023","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.06.020_bib18","doi-asserted-by":"crossref","first-page":"S675","DOI":"10.14309\/01.ajg.0000953264.39304.09","article-title":"S906 Efficacy and durability of ozanimod by baseline endoscopic disease activity in advanced therapy\u2013naive ulcerative colitis patients suboptimally controlled on conventional therapies","volume":"118","author":"Rubin","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2025.06.020_bib19","doi-asserted-by":"crossref","first-page":"i2149","DOI":"10.1093\/ecco-jcc\/jjae190.1357","article-title":"Multivariable analysis of baseline variables associated with efficacy outcomes in the ELEVATE UC clinical programme","volume":"19","author":"Feagan","year":"2025","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.cgh.2025.06.020_bib20","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/ecco-jcc\/jjae038","article-title":"Efficacy and safety of etrasimod in patients with moderately to severely active isolated proctitis: results from the phase 3 ELEVATE UC clinical programme","volume":"18","author":"Peyrin-Biroulet","year":"2024","journal-title":"J Crohns Colitis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525005427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356525005427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T07:35:42Z","timestamp":1779953742000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356525005427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S1542356525005427"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2025.06.020","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of Etrasimod in Ulcerative Colitis: Analysis of ELEVATE UC 52 and ELEVATE UC 12 by Baseline Endoscopic Severity","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2025.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of the AGA Institute.","name":"copyright","label":"Copyright"}]}}